Allogene Therapeutics, Inc. - Laporan Laba Rugi (TTM)

Allogene Therapeutics, Inc.
US ˙ NasdaqGS ˙ US0197701065

Laporan Laba Rugi (TTM)

Laporan Laba Rugi Allogene Therapeutics, Inc. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 38 38 38 114 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Change (%) 0.11 0.13 196.81 -99.82 20.49 0.00 -36.84 -19.87 -51.20 -44.26 179.41 -8.42 -25.29 -33.85 -48.84 -100.00 NaN
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 248 211 218 220 225 230 235 256 276 281 264 243 215 203 202 192 190 180
Change (%) -14.93 3.46 0.80 2.26 2.17 2.14 9.12 7.83 1.76 -6.28 -7.87 -11.52 -5.44 -0.62 -4.80 -1.07 -5.36
% of Revenue 647.20 549.96 568.24 192.99 109,828.78 93,129.55 95,121.86 164,350.64 221,175.20 461,206.56 775,505.88 255,698.95 247,051.72 312,695.38 469,739.53 874,086.36
Gross Operating Profit -210 -173 -180 -106 -225 -230 -235 -256 -276 -281 -264 -243 -215 -203 -202 -192 -190 -180
Change (%) -17.68 4.20 -41.06 112.04 2.15 2.14 9.17 7.85 1.78 -6.27 -7.90 -11.52 -5.43 -0.61 -4.79 -1.06 -5.36
% of Revenue -547.20 -449.96 -468.24 -92.99 -109,728.78 -93,029.55 -95,021.86 -164,250.64 -221,075.20 -461,106.56 -775,405.88 -255,598.95 -246,951.72 -312,595.38 -469,639.53 -873,986.36
SG&A 66 69 71 74 78 78 78 79 78 77 75 72 70 68 67 65 63 61
Change (%) 4.43 3.45 3.97 4.77 0.94 -0.13 1.33 -1.28 -1.26 -2.40 -5.01 -2.26 -3.48 -1.05 -2.55 -3.49 -2.87
% of Revenue 172.06 179.48 185.44 64.95 37,872.68 31,726.72 31,685.83 50,836.54 62,633.60 126,732.79 221,914.71 75,445.26 80,524.14 104,029.23 155,606.98 296,386.36
R&D -42
Change (%)
% of Revenue -109.64
OpEx 272 280 290 294 303 308 313 336 355 359 339 315 285 271 269 258 253 241
Change (%) 2.91 3.46 1.58 2.89 1.85 1.56 7.18 5.68 1.09 -5.44 -7.24 -9.41 -4.95 -0.73 -4.24 -1.68 -4.74
% of Revenue 709.63 729.44 753.68 257.94 147,701.46 124,856.28 126,807.69 215,187.18 283,808.80 587,939.34 997,420.59 331,144.21 327,575.86 416,724.62 625,346.51 1,170,472.73
Operating Income -234 -242 -251 -180 -303 -308 -313 -336 -355 -359 -339 -314 -285 -271 -269 -257 -253 -241
Change (%) 3.37 3.98 -28.28 67.92 1.84 1.56 7.21 5.69 1.11 -5.44 -7.25 -9.41 -4.95 -0.72 -4.23 -1.68 -4.74
% of Revenue -609.63 -629.44 -653.68 -157.94 -147,601.46 -124,756.28 -126,707.69 -215,087.18 -283,708.80 -587,839.34 -997,320.59 -331,044.21 -327,475.86 -416,624.62 -625,246.51 -1,170,372.73
Interest Expense -0 -0 -0 -1
Change (%) 81.00 82.87 80.97
% of Revenue -232.56 -822.73
Net Income -229 -239 -251 -182 -304 -308 -313 -340 -361 -365 -344 -327 -292 -279 -283 -258 -252 -237
Change (%) 4.35 5.02 -27.38 66.90 1.27 1.61 8.88 5.91 1.23 -5.72 -4.90 -10.68 -4.40 1.43 -9.12 -2.04 -6.11
% of Revenue -596.57 -621.84 -652.24 -159.57 -148,214.63 -124,571.26 -126,580.16 -218,214.10 -288,425.60 -598,322.95 -1,012,105.88 -344,489.47 -335,973.56 -429,881.54 -659,137.21 -1,170,863.64

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista